<DOC>
	<DOCNO>NCT02267135</DOCNO>
	<brief_summary>This study ass efficacy safety secukinumab compare placebo adult patient moderate severe scalp psoriasis poorly control current psoriasis treatment .</brief_summary>
	<brief_title>Efficacy Safety Subcutaneous Secukinumab Adults With Moderate Severe Scalp Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Chronic scalp psoriasis least previous six month Moderate severe scalp psoriasis define PSSI score ≥12 30 % high scalp surface area affect Must candidate systemic therapy , mean scalp psoriasis inadequately control topical treatment ( corticosteroid ) , and/or phototherapy , and/or previous systemic therapy . Forms psoriasis chronic plaque Druginduced psoriasis ( e.g. , new onset current exacerbation βblockers , calcium channel inhibitor ) Ongoing use prohibit treatment ( e.g. , topical systemic corticosteroid , UV therapy ) Prior exposure secukinumab ( AIN457 ) biologic drug directly target IL17A IL17RA receptor Use investigational drug within 30 day prior study entry , within period 5 halflives investigational treatment , whichever longer Active , ongoing inflammatory disease psoriasis might confound evaluation benefit secukinumab Active system infection ( exception common cold ) two week prior start study treatment Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>scalp psoriasis , plaque psoriasis , secukinumab , AIN457 , biologic , monoclonal antibody , psoriasis , AIN457A</keyword>
</DOC>